Log in

Relevant bibliographies by topics / Voriconazole

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Voriconazole'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Voriconazole.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Voriconazole"

1

Encalada Ventura, M. A., L. F. R. Span, E. R. van den Heuvel, G. M. M. Groothuis, and J. W. C. Alffenaar. "Influence of Inflammation on Voriconazole Metabolism." Antimicrobial Agents and Chemotherapy 59, no. 5 (2015): 2942–43. http://dx.doi.org/10.1128/aac.04789-14.

Full text

Abstract:

ABSTRACTVoriconazole pharmacokinetics shows a large inter- and intrapatient variability. Inflammation is associated with changes in the expression of CYP isoenzymes. Here, we evaluated the influence of inflammation, marked by C-reactive protein (CRP) levels in blood, on the metabolism of voriconazole. Observational data showed an association between CRP level and the ratio of voriconazoleN-oxide to voriconazole.

APA, Harvard, Vancouver, ISO, and other styles

2

Singh, Sumita, Vaishali M. Patil, and Sarvesh Kumar Paliwal. "FABRICATION, CHARACTERIZATION AND IN VITRO ANTIFUNGAL ASSESSMENT OF VORICONAZOLE NANOEMULSION." INDIAN DRUGS 62, no. 02 (2025): 31–41. https://doi.org/10.53879/id.62.02.15135.

Full text

Abstract:

Voriconazole, a potent antifungal agent, faces challenges related to poor water solubility and bioavailability, limiting its clinical efficacy. Nanoemulsions offer a promising approach to enhancing drug solubility, stability and potentially improving therapeutic outcomes. This work aims to fabricate a voriconazole-loaded nanoemulsion and to evaluate its in vitro antifungal activity against common fungal pathogens. Voriconazole nanoemulsions were fabricated using the aqueous titration method. Different oil phases, co-surfactants, and surfactants were assessed to optimize the formulation. Among

APA, Harvard, Vancouver, ISO, and other styles

3

Zhao, Yi-Chang, Yang Zou, Jing-Jing Hou, et al. "Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children." Antibiotics 10, no. 12 (2021): 1542. http://dx.doi.org/10.3390/antibiotics10121542.

Full text

Abstract:

Voriconazole is a triazole antifungal agent commonly used for the treatment and prevention of invasive aspergillosis (IA). However, the study of voriconazole's use in children is limited. The present study was performed to explore maintenance dose to optimize voriconazole dosage in children and the factors affecting voriconazole trough concentration. This is a non-interventional retrospective clinical study conducted from 1 January 2016 to 31 December 2020. The study finally included 94 children with 145 voriconazole trough concentrations. The probability of achieving a targeted concentration

APA, Harvard, Vancouver, ISO, and other styles

4

Oude Lashof, A. M. L., J. D. Sobel, M. Ruhnke, et al. "Safety and Tolerability of Voriconazole in Patients with Baseline Renal Insufficiency and Candidemia." Antimicrobial Agents and Chemotherapy 56, no. 6 (2012): 3133–37. http://dx.doi.org/10.1128/aac.05841-11.

Full text

Abstract:

ABSTRACTAcutely ill patients with candidemia frequently suffer from renal insufficiency. Voriconazole's intravenous formulation with sulfobutylether beta-cyclodextrin (SBECD) is restricted in patients with renal insufficiency. We evaluated the use of intravenous voriconazole formulated with SBECD in candidemic patients with renal insufficiency and compared treatment outcome and safety to those who received a short course of amphotericin B deoxycholate followed by fluconazole. We reviewed data on treatment outcome, survival, safety, and tolerability from the subset of patients with moderate (cr

APA, Harvard, Vancouver, ISO, and other styles

5

Zarrin, Majid, and Sama Faramarzi. "Study of Azole - Resistant and Cyp51a Gene in Aspergillus Fumigatus." Open Access Macedonian Journal of Medical Sciences 6, no. 5 (2018): 747–50. http://dx.doi.org/10.3889/oamjms.2018.171.

Full text

Abstract:

AIM: The main goal of the present study was to find azole-resistant and molecular analysis of cyp51A gene in Aspergillus fumigatus.MATERIALS AND METHODS: Fifty-eight A. fumigatus strains including environmental, clinical and reference isolates were assessed in this investigation. Azole susceptibility testing for itraconazole and voriconazole was carried out for A. fumigatus isolates. PCR was performed based on cyp51A gene sequence for all isolates.RESULTS: Susceptibility testing verified the minimum inhibitory concentrations (MICs) for itraconazole (0.125 to 2 µg/ml) and voriconazole (0.125 to

APA, Harvard, Vancouver, ISO, and other styles

6

Aryati, Yulia Ayu, and Elfa Ali Idrus. "Effectiveness of Voriconazole in Treating Fungal Keratitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." MPI (Media Pharmaceutica Indonesiana) 4, no. 2 (2022): 195–206. http://dx.doi.org/10.24123/mpi.v4i2.5284.

Full text

Abstract:

    Antifungal intervention fails in approximately half of fungal keratitis patients, demonstrating its limitations. Voriconazole use for fungal keratitis has raised new interest because of its broad spectrum and good ocular penetration. However, its effectiveness has not been systematically evaluated. Here we try to clarify the benefits of voriconazole in fungal keratitis cases. Randomized controlled trials (RCTs) comparing voriconazole to placebo or other antifungal medications for fungal keratitis were searched in several databases, including PubMed, Scopus, Cochra

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Voriconazole." Reactions Weekly &NA;, no. 1379 (2011): 37. http://dx.doi.org/10.2165/00128415-201113790-00140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Voriconazole." Reactions Weekly &NA;, no. 1380 (2011): 42. http://dx.doi.org/10.2165/00128415-201113800-00150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

&NA;. "Voriconazole." Reactions Weekly &NA;, no. 1385 (2012): 45. http://dx.doi.org/10.2165/00128415-201213850-00165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Voriconazole." Reactions Weekly &NA;, no. 1386 (2012): 36–37. http://dx.doi.org/10.2165/00128415-201213860-00128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Voriconazole"

1

Chan, Hui Min Ravis William R. "Pharmacokinetics of Voriconazole in horses and alpacas." Auburn, Ala, 2008. http://repo.lib.auburn.edu/EtdRoot/2008/SPRING/Pharmacal_Sciences/Dissertation/Chan_Hui_20.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hackman, Christine, Dory Hardy, and Kathryn Matthias. "Comparison of Characteristics of Patients who Received Posaconazole or Voriconazole for the Treatment of Coccidioidomycosis." The University of Arizona, 2013. http://hdl.handle.net/10150/614261.

Full text

Abstract:

Class of 2013 Abstract<br>Specific Aims: To describe the characteristics of patients who were switched to or prescribed posaconazole or voriconazole for the treatment of coccidioidomycosis including duration of previous anti-fungal treatment and rationale for changing from the first-line agents to posaconazole or voriconazole. Methods: This was a retrospective medical chart review of all patients admitted to an academic medical center with a diagnosis of coccidioidomycosis and prescribed posaconazole or voriconazole between January 2008 and December 2011. Subjects for the study were iden

APA, Harvard, Vancouver, ISO, and other styles

3

Jeans, Adam Rupert. "The pharmacodynamics of antifungal agents against Aspergillus." Thesis, University of Manchester, 2013. https://www.research.manchester.ac.uk/portal/en/theses/the-pharmacodynamics-of-antifungal-agents-against-aspergillus(42f0da51-46dc-4960-9912-d47e7871f496).html.

Full text

Abstract:

Background: Voriconazole is a first line agent for the treatment for invasive pulmonary aspergillosis. There are increasing reports of Aspergillus fumigatus isolates with reduced susceptibility to voriconazole. I investigated the pharmacodynamics of voriconazole against drug susceptible and drug resistant strains of Aspergillus fumigatus through the development of a novel dynamic in vitro model of the human alveolus. I then investigated whether combination therapy with voriconazole and anidulafungin would be beneficial in the treatment of infection with these isolates. Methods: An in vitro dyn

APA, Harvard, Vancouver, ISO, and other styles

4

Nguyen, Jill, Sarah Workinger, and Kathryn Matthias. "Evaluation of Prophylactic Voriconazole and Posaconazole Concentration Monitoring and Dose Changes in Liquid and Solid Transplant Patients." The University of Arizona, 2012. http://hdl.handle.net/10150/614520.

Full text

Abstract:

Class of 2012 Abstract<br>Specific Aims: The primary aim of this study was to determine the incidence of posaconazole and voriconazole concentration monitoring that occurs in transplant patients receiving antifungal prophylaxis therapy. The secondary aim was to determine whether voriconazole and posaconazole serum concentrations were used for dose adjustments. Methods: Patients status post either a liquid or solid organ transplant over the age of 1 year who received invasive fungal infection prophylaxis with either posaconazole or voriconazole between the dates of February 1, 2010 through

APA, Harvard, Vancouver, ISO, and other styles

5

Rocha, Kamilla Amaral David. "Desenvolvimento de formulações contendo voriconazol encapsulado em nanopartículas lipídicas e promotores químicos de absorção para aplicação tópica na unha." Universidade Federal de Goiás, 2015. http://repositorio.bc.ufg.br/tede/handle/tede/8190.

Full text

Abstract:

Submitted by Liliane Ferreira (ljuvencia30@gmail.com) on 2018-02-28T14:49:21Z No. of bitstreams: 2 Dissertação - Kamilla Amaral David Rocha - 2015.pdf: 3193387 bytes, checksum: 6cc146ed197535b6a21627e8ffa4891c (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)<br>Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2018-02-28T16:16:32Z (GMT) No. of bitstreams: 2 Dissertação - Kamilla Amaral David Rocha - 2015.pdf: 3193387 bytes, checksum: 6cc146ed197535b6a21627e8ffa4891c (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5

APA, Harvard, Vancouver, ISO, and other styles

6

Valle, T. Figueras José María. "Variabilitat, efectivitat i seguretat del voriconazole en la infecció fúngica invasiva a pediatria." Doctoral thesis, Universitat Autònoma de Barcelona, 2020. http://hdl.handle.net/10803/670947.

Full text

Abstract:

Introducció. Les concentracions plasmàtiques (CP) de voriconazole (VCZ) tenen una elevada variabilitat. El 2012 va canviar la posologia del VCZ a pediatria. Existeixen poques dades pediàtriques sobre el monitoratge de CP (MCP) de VCZ amb la dosificació actual. Es pretén avaluar el MCP i descriure la seva relació amb l’efectivitat i seguretat del tractament de la infecció fúngica invasiva (IFI) a pediatria amb la nova posologia. Mètodes. Estudi prospectiu observacional unicèntric, realitzat des de gener de 2014 fins agost de 2018 amb pacients de 2-12 anys en tractament amb VCZ a les dosis a

APA, Harvard, Vancouver, ISO, and other styles

7

Debourgogne, Anne. "Typage moléculaire du complexe d'espèces Fusarium solani et détermination de son mécanisme de résistance au voriconazole." Thesis, Université de Lorraine, 2013. http://www.theses.fr/2013LORR0021/document.

Full text

Abstract:

Le complexe d'espèces Fusarium solani regroupe des champignons phytopathogènes également impliqués en pathologie humaine dans des infections parfois profondes et souvent de mauvais pronostic. Dans un premier temps, une méthode de MLST, s'appuyant sur 5 gènes de ménage a donc été développée. Validée sur 51 isolats épidémiologiquement distincts, cette méthode stable et reproductible présente un pouvoir discriminant de 99,1 %. Après comparaison à la technique de référence utilisée en phylogénie, un schéma consensus à 8 loci a été proposé. Dans un second temps, une étude de la sensibilité de ce pa

APA, Harvard, Vancouver, ISO, and other styles

8

Gueudry, Julie. "Contribution à l'étude de nouveaux agents antiamibiens dans un modèle expérimental de kératite à Acanthamoeba chez le rat." Thesis, Normandie, 2018. http://www.theses.fr/2018NORMR057.

Full text

Abstract:

La kératite à Acanthamoeba (KA) est une kératite infectieuse rare et grave,potentiellement cécitante. L'infection est causée par Acanthamoeba spp., unprotozoaire ubiquitaire présent dans le sol, l'air et l'eau. Jusqu'à 85% des cas de KAsont associés au port de lentilles cornéennes, et plus rarement suite à untraumatisme.Actuellement, aucune molécule n’a d’autorisation de mise sur le marché danscette indication dans l'Union européenne et aux États-Unis. Ces dernières années,des combinaisons d'agents anti-amibiens tels que les biguanides et les diamidinesont été utilisées comme traitement de réf

APA, Harvard, Vancouver, ISO, and other styles

9

Araújo, Bibiana Verlindo de. "Modelagem farmacocinética-farmacodinâmica do antifúngico voriconazol." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2008. http://hdl.handle.net/10183/12602.

Full text

Abstract:

Objetivos: O objetivo deste trabalho foi o desenvolvimento de um modelo farmacocinético/farmacodinâmico (PK/PD) para descrever o efeito antifúngico voriconazol (VRC) contra espécies de Candida. Método: Para alcançar este objetivo as seguintes etapas foram realizadas: i) foi adaptado e padronizado modelo de candidíase disseminada em ratos Wistar imunocompetentes e imunocomprometidos com Candida sp.; ii) foram validados métodos analíticos de LC-MS/MS e LC-UV para o doseamento do VRC em amostras de plasma e microdialisado de tecido; iii) foram estabelecidas as condições para microdiálise do VRC e

APA, Harvard, Vancouver, ISO, and other styles

10

Ribeiro, Aline Dias. "Ocorrência de infecção nosocomial por Candida spp. no Hospital Universitário Cassiano Antonio de Moraes (HUCAM) e avaliação da anfotericina b e voriconazol na inibição de formação de biofilme pelas espécies isoladas." Universidade Federal do Espírito Santo, 2013. http://repositorio.ufes.br/handle/10/5887.

Full text

Abstract:

Made available in DSpace on 2016-12-23T13:55:58Z (GMT). No. of bitstreams: 1 Aline Dias Ribeiro.pdf: 1981766 bytes, checksum: cf9b688ead72c08ab9f20a3a8c84afcc (MD5) Previous issue date: 2013-08-09<br>INTRODUÇÃO: Infecções de corrente sanguínea por fungos têm se destacado principalmente pelo crescente número de casos de candidemia (infecções por Candida spp neste sítio). Atualmente, este fungo figura como um dos sete patógenos mais comuns em infecções nosocomiais, apresentando taxas de mortalidade bruta entre 40 e 70% e atribuída, de 50%. Formação de biofilme é frequentemente associada a pers

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Voriconazole"

1

Blokdijk, G. J. Voriconazole; A Clear and Concise Reference. CreateSpace Independent Publishing Platform, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Angelini, Andrea. Voriconazole: Pharmacokinetics, Role in Therapeutic Drug Monitoring and Clinical Outcomes. Nova Science Publishers, Incorporated, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

White, Steven. Voriconazole: Effective Treatment for Esophageal Candidiasis Infection, Infections of the Skin, Stomach, Kidney, Bladder, and Wounds. Etc. Independently Published, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ashbee, H. Ruth. Antifungal therapeutic drug monitoring. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0048.

Full text

Abstract:

Therapeutic drug monitoring (TDM), the process of measuring drug concentrations in patients at specified time intervals, aims to ensure that the drug concentrations remain within the efficacious and non-toxic range for that drug. This chapter reviews the rationale for the use of TDM in antifungal therapy, specifically for flucytosine and azoles, including fluconazole, itraconazole, voriconazole, and posaconazole. For each antifungal drug, the bioavailability and excretion of the drug are detailed, as well as specific factors affecting antifungal drug concentrations in patients. The chapter dis

APA, Harvard, Vancouver, ISO, and other styles

5

Bicanic, Tihana, and Thomas S. Harrison. Fungal central nervous system infections. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0022.

Full text

Abstract:

Infections of the central nervous system (CNS) are amongst the most severe of all fungal infections. Cryptococcus neoformans is the commonest cause of adult meningitis in many countries with high HIV prevalence. C gattii is usually seen in the tropics in apparently immunocompetent patients. Meningitis is also caused by Candida in premature babies, and by the dimorphic fungi in endemic areas. CNS infections with Aspergillus, the mucormycetes, and less common moulds usually present as intracranial mass lesions in immunocompromised hosts. Early suspicion, prompt imaging, and appropriate samples f

APA, Harvard, Vancouver, ISO, and other styles

6

Jacobs, Samantha E., Catherine B. Small, and Thomas J. Walsh. Fungal diseases of the respiratory tract. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0030.

Full text

Abstract:

Fungal respiratory infections are important causes of morbidity and mortality in immunocompromised patients. Invasive aspergillosis remains the most common invasive fungal infection whereas other filamentous fungi, such as Fusarium spp., Mucorales, and Scedosporium spp., are increasing in frequency, particularly in neutropenic hosts. Endemic mycoses, including those due to Histoplasma capsulatum, Coccidioides spp., and Talaromyces marneffei, are increasingly prevalent in patients with cell-mediated immunodeficiencies in respective geographic regions. Culture remains the gold standard of diagno

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Voriconazole"

1

Mehlhorn, Heinz. "Voriconazole." In Encyclopedia of Parasitology. Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-43978-4_4924.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mehlhorn, Heinz. "Voriconazole." In Encyclopedia of Parasitology. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27769-6_4924-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Girton, Mark, Jose Tomsig, and Lindsay Bazydlo. "Triazole Antifungal Quantification for Therapeutic Drug Monitoring in Serum by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): Posaconazole, Voriconazole, Itraconazole, and Hydroxyitraconazole." In Methods in Molecular Biology. Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-3541-4_6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Molinelli, Alejandro R., and Charles H. Rose. "Quantification of the Triazole Antifungal Compounds Voriconazole and Posaconazole in Human Serum or Plasma Using Liquid Chromatography Electrospray Tandem Mass Spectrometry (HPLC-ESI-MS/MS)." In Methods in Molecular Biology. Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3252-8_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

"Voriconazole." In Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Elsevier, 2006. http://dx.doi.org/10.1016/b0-44-451005-2/00529-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Papich, Mark G. "Voriconazole." In Saunders Handbook of Veterinary Drugs. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-24485-5.00590-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Chevrel, Guillaume, and Virginie Dessus. "voriconazole." In 300 médicaments injectables. Elsevier, 2009. http://dx.doi.org/10.1016/b978-2-294-70698-1.50167-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

"Voriconazole." In Meyler's Side Effects of Drugs. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-444-53717-1.01643-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

"Voriconazole." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-1868.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Simpson, Michelle C., and Eric G. Schaefer. "Voriconazole." In Extended Stability for Parenteral Drugs. ASHP, 2022. http://dx.doi.org/10.37573/9781585286720.193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Voriconazole"

1

Moya Mangas, C., L. Amaro, MJ Tirado, and V. Merino. "4CPS-139 Voriconazole serum concentrations monitoring." In 28th EAHP Congress, Bordeaux, France, 20-21-22 March 2024. British Medical Journal Publishing Group, 2024. http://dx.doi.org/10.1136/ejhpharm-2024-eahp.243.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ruiz Boy, S., N. Socoro-Yuste, C. Bastida, and D. Soy-Muner. "4CPS-057 Therapeutic drug monitoring of voriconazole." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.158.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hilberg, Ole, Elisabeth Bendstrup, Jann Mortensen, and Charlotte Andersen. "Inhaled Voriconazole - An Efficient Treatment Against Invasive Aspergillosis." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Pantović, Bojana V., Nevena Lj Stevanović, Tina P. Andrejević, Darko P. Ašanin, Miloš I. Djuran, and Biljana Đ. Glišić. "DNA/BSA binding study of mononuclear gold(III) complexes with clinically used azoles." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.399p.

Full text

Abstract:

In the present study, we investigated the interactions of three mononuclear gold(III) complexes of the general formula [AuCl3(azole)], azole is clotrimazole (ctz, Au1), tioconazole (tcz, Au2) and voriconazole (vcz, Au3) with calf thymus DNA (ct-DNA) and bovine serum albumin (BSA) by fluorescence emission spectroscopy. A significant decrease in fluorescence intensity of BSA in the presence of the complexes and high values of the calculated binding constants have indicated their good binding affinity toward this model protein. Besides that, the investigated Au1-3 complexes have shown a significa

APA, Harvard, Vancouver, ISO, and other styles

5

Pirrone, A., FN Beretta, L. Gambitta, and V. Marini. "5PSQ-045 Cost-effectiveness analysis of isavuconazole versus voriconazole." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.399.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Voralia, Neha, Orlagh McGarrity, and Lucy Craig. "221 Outpatient voriconazole therapeutic drug monitoring: what went wrong?" In GOSH Conference 2024. BMJ Publishing Group Ltd, 2025. https://doi.org/10.1136/bmjpo-2025-gosh.118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gutiérrez Palomo, S., IM Moreno Escudero, A. Rochina Astorga, A. Quesada Asencio, L. Peral Ballester, and A. Navarro Ruiz. "3PC-033 Intracameral and intrastromal voriconazole administration in fusarium keratitis." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.80.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Nishihara, F., T. Hirama, S. Maesaki, et al. "Treatment of Chronic Pulmonary Aspergillosis by Voriconazole Compared with Micafungin." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5936.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Taberner Bonastre, P., A. Aragones Eroles, M. Martinez Sogues, et al. "4CPS-112 Voriconazole therapeutic drug monitoring: relationship with liver toxicity." In 26th EAHP Congress, Hospital pharmacists – changing roles in a changing world, 23–25 March 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/ejhpharm-2022-eahp.140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Idoate, AI, L. Leache, and A. Aldaz. "4CPS-058 Avoid simultaneus prescription between linezolid and voriconazole: pharmacokinetic study." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Voriconazole"

1

Maheshwari, E. Uma, and G. Jyothilakshmi. A STUDY OF ANTIFUNGAL SUSCEPTIBILITY TESTING AMONG NON ALBICANS CANDIDA IN PATIENTS OF VULVO VAGINAL CANDIDIASIS AT TERTIARY CARE CENTER. World Wide Journals, 2023. http://dx.doi.org/10.36106/ijar/9605846.

Full text

Abstract:

Background &objectives: Candida species are emerging as a signicant pathogen certain species of Candida like Candida krusei are inherently resistant to azoles. In vitro susceptibility testing is essential for guiding therapy. The present study aims todetermine the antifungal susceptibility pattern ofNon albicansCandida isolates by disc diffusion and micro broth dilution method. Methods:This was a prospective study, conducted among 200 patients complaining of Vulvovaginal dischargeSpeciation was done as per standard microbiological methods. Non albicans Candida species were identied. Anti

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!